News

Sarepta Therapeutics Announces Second Quarter 2025 Financial Results and Recent Corporate Developments
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the second quarter of 2025.
FS KKR Capital Corp. Announces Second Quarter 2025 Results
FS KKR Capital Corp. (NYSE: FSK), or the Company, today announced its financial and operating results for the quarter ended June 30, 2025, and that its board of directors has declared a third quarter 2025 distribution of $0.
Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update
NDA for icotrokinra for the treatment of adults and adolescents 12 years of age and older with moderate to severe plaque psoriasis (PsO) submitted to U.S. FDA in July ANTHEM Phase 2b trial data of icotrokinra in ulcerative colitis scheduled for an oral presentation at the 33rd United European Gastroenterology Week (UEGW) on October 7th
NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results
Announced strategic partnership with Simcere Zaiming for Phase 1 program SIM0505 (CDH6 ADC) with plans to dose the first SIM0505 patient in the United States this quarterCurrently in cohort 4
GoDaddy Inc. Reports Second Quarter 2025 Financial Results
GoDaddy Inc. (NYSE: GDDY) today reported second quarter 2025 financial results. To view the earnings release, earnings presentation and prepared remarks, please access the company's Investor Relations website at GoDaddy management will host a live webcast at 5:00 p.

Sarepta says it won't comply with FDA request to stop shipping gene therapy Elevidys

U.S. regulators asked Sarepta Therapeutics on Friday to voluntarily halt shipments of its Elevidys gene therapy after a ...

FDA’s Prasad Exits Following Political Backlash Over Sarepta

Vinay Prasad, a top regulator at the US Food and Drug Administration, has left the agency after a controversy over his ...
BioSpace4d

‘Unprecedented’ FDA Leaks Sow Confusion For Patients, Sarepta and Capricor

Sarepta and Capricor learned of key regulatory decisions from the media and investors, and Duchenne muscular dystrophy ...

Sarepta will resume gene therapy shipments after FDA review of recent patient death

Shares of drugmaker Sarepta Therapeutics surged in afterhours trading Monday after the company said it would resume shipping ...

Sarepta Soars After FDA Says Some Patients Can Get Elevidys

In a major win for Sarepta Therapeutics Inc., US regulators are recommending that patients who can walk be allowed to take ...
Fierce Pharma1d

Sarepta, with $1B in debts due in 2027, weighs efficiency measures

After a second Elevidys patient death from acute liver failure, Sarepta in July launched a major restructuring that involves ...

Sarepta reportedly hired Trump-linked lobbying firm after gene therapy deaths

Sarepta Therapeutics (SRPT) stock in focus as report says company hired a Trump-linked lobbying firm after deaths linked to ...

FDA probes death of patient on Sarepta's Elevidys, partner Roche says death unrelated to therapy

The U.S. Food and Drug Administration said on Friday it was investigating the death of an eight-year-old boy who received ...
STAT2d

Sarepta hired a Trump-connected firm to lobby on Duchenne treatment

Sarepta Therapeutics hired a Trump-connected lobbying firm after the death of a teenage boy treated with its Duchenne ...

Sarepta shares slide again as drugmaker bows to FDA pressure to pause gene therapy

Sarepta Therapeutics is pausing shipments of its gene therapy for muscular dystrophy following several patient deaths that have attracted attention from regulators ...
BioSpace10d

FDA Does 180 on Sarepta, Freeing DMD Gene Therapy for Ambulatory Patients

The swift FDA action removes an overhang from Sarepta and allows Elevidys to return to the market without another safety ...